An update on cardio-oncology

Trends in Cardiovascular Medicine

Volumn 24, Issue 7, 2014, Pages 285-295

  Herrmann, Joerg ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARVEDILOL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; NILOTINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART RHYTHM; HUMAN; REVIEW; THREE DIMENSIONAL ECHOCARDIOGRAPHY; VASCULAR DISEASE; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMORBIDITY; NEOPLASMS; ODDS RATIO; ONCOLOGY; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME;

EID: 84908028393     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.07.003     Document Type: Review

References (101)

1. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
2. Minotti G., Cairo G., Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J 1999, 13:199-212.
3. Lebrecht D., Walker U.A. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7:108-113.
4. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007, 23:15-25.
5. Zhang S., Liu X., Bawa-Khalfe T., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
6. Ky B., Vejpongsa P., Yeh E.T., Force T., Moslehi J.J. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013, 113:754-764.
7. Piegari E., De Angelis A., Cappetta D., et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol 2013, 108:334.
8. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, 2:CD003917.
9. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, 6:CD003917.
10. Kalam K., Marwick T.H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013, 49:2900-2909.
11. El-Shitany N.A., Tolba O.A., El-Shanshory M.R., El-Hawary E.E. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail 2012, 18:607-613.
12. Kaya M.G., Ozkan M., Gunebakmaz O., et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013, 167:2306-2310.
13. Bosch X., Rovira M., Sitges M., et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013, 61:2355-2362.
14. Zhao Y., McLaughlin D., Robinson E., et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 2010, 70:9287-9297.
15. Jo S.H., Kim L.S., Kim S.A., et al. Evaluation of short-term use of N-Acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: EPOCH Trial-a Prospective randomized study. Korean Circ J 2013, 43:174-181.
16. Lotrionte M., Biondi-Zoccai G., Abbate A., et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013, 112:1980-1984.
17. Drafts B.C., Twomley K.M., D'Agostino R., et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013, 6:877-885.
18. Sawaya H., Sebag I.A., Plana J.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012, 5:596-603.
19. Poterucha J.T., Kutty S., Lindquist R.K., Li L., Eidem B.W. Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr 2012, 25:733-740.
20. Florescu M., Magda L.S., Enescu O.A., Jinga D., Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr 2014, 27:83-92.
21. Kang Y., Xu X., Cheng L., et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail 2014, 16:300-308.
22. Thavendiranathan P., Poulin F., Lim K.D., Plana J.C., Woo A., Marwick T.H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy-a systematic review. J Am Coll Cardiol 2014, 63:2751-2768.
23. Mornos C., Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol 2013, 91:601-607.
24. Motoki H., Koyama J., Nakazawa H., et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging 2012, 13:95-103.
25. Toro-Salazar O.H., Gillan E., O'Loughlin M.T., et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013, 6:873-880.
26. Tham E.B., Haykowsky M.J., Chow K., et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson 2013, 15:48.
27. Neilan T.G., Coelho-Filho O.R., Pena-Herrera D., et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012, 110:1679-1686.
28. Ylanen K., Poutanen T., Savikurki-Heikkila P., Rinta-Kiikka I., Eerola A., Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 2013, 61:1539-1547.
29. Armstrong G.T., Plana J.C., Zhang N., et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012, 30:2876-2884.
30. Thavendiranathan P., Grant A.D., Negishi T., Plana J.C., Popovic Z.B., Marwick T.H. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013, 61:77-84.
31. Ylanen K., Eerola A., Vettenranta K., Poutanen T. Three-dimensional echocardiography and cardiac magnetic resonance imaging in the screening of long-term survivors of childhood cancer after cardiotoxic therapy. Am J Cardiol 2014, 113:1886-1892.
32. Watts R.G., George M., Johnson W.H. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center. Cancer 2012, 118:1919-1924.
33. Lipshultz S.E., Adams M.J., Colan S.D., et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1995.
34. Wong F.L., Bhatia S., Landier W., et al. Cost-effectiveness of the Children's Oncology Group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 2014, 160:672-683.
35. Yeh J.M., Nohria A., Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014, 160:661-671.
36. Bryant A., Sheppard D., Sabloff M., et al. A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with AML. Leuk Lymphoma 2014, 1-17.
37. Jurczak W., Szmit S., Sobocinski M., et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen-a national multicenter study. Int J Cardiol 2013, 168:5212-5217.
38. Cascales A., Pastor-Quirante F., Sanchez-Vega B., et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist 2013, 18:446-453.
39. McCaffrey T.A., Tziros C., Lewis J., et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. Int J Biol Sci 2013, 9:350-360.
40. Visscher H., Ross C.J., Rassekh S.R., et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013, 60:1375-1381.
41. Visscher H., Ross C.J., Rassekh S.R., et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012, 30:1422-1428.
42. Ky B., Putt M., Sawaya H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014, 63:809-816.
43. Carboni G.P. A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy. Am J Cardiovasc Dis 2012, 2:293-300.
44. Piwnica-Worms D., Chiu M.L., Kronauge J.F. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol 1993, 32:385-391.
45. Borde C., Kand P., Basu S. Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: evidence of early chemotherapeutic cardiotoxicity?. World J Radiol 2012, 4:220-223.
46. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
47. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
48. ElZarrad M.K., Mukhopadhyay P., Mohan N., et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 2013, 8:e79543.
49. Barth A.S., Zhang Y., Li T., et al. Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl Med 2012, 1:289-297.
50. Mokuyasu S., Suzuki Y., Kawahara E., Seto T., Tokuda Y. High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer. Breast Cancer 2014, 10.1007/s12282-014-0520-8.
51. Morris P.G., Chen C., Steingart R., et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 2011, 17:3490-3499.
52. Cardinale D., Colombo A., Torrisi R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28:3910-3916.
53. Fallah-Rad N., Lytwyn M., Fang T., Kirkpatrick I., Jassal D.S. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008, 10:5.
54. Stokkel M.P., de Wit-van der Veen L.J., Boekhout A. I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: the first experience. Nucl Med Commun 2013, 34:19-24.
55. de Azambuja E., Procter M.J., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant Trial (BIG 1-01). J Clin Oncol 2014, 10.1200/JCO.2013.53.9288.
56. Chen J., Long J.B., Hurria A., Owusu C., Steingart R.M., Gross C.P. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012, 60:2504-2512.
57. Chen T., Xu T., Li Y., et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 2011, 37:312-320.
58. Bonifazi M., Franchi M., Rossi M., et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist 2013, 18:795-801.
59. Serrano C., Cortes J., De Mattos-Arruda L., et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012, 23:897-902.
60. Chavez-MacGregor M., Zhang N., Buchholz T.A., et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013, 31:4222-4228.
61. Russo G., Cioffi G., Gori S., et al. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med (Hagerstown) 2014, 15:141-146.
62. Farolfi A., Melegari E., Aquilina M., et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 2013, 99:634-639.
63. Cochet A., Quilichini G., Dygai-Cochet I., et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 2011, 130:845-854.
64. Russo G., Cioffi G., Di Lenarda A., et al. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 2012, 7:439-446.
65. Lemieux J., Diorio C., Cote M.A., et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013, 33:2569-2576.
66. Ezaz G., Long J.B., Gross C.P., Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014, 3:e000472.
67. Negishi K., Negishi T., Hare J.L., Haluska B.A., Plana J.C., Marwick T.H. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013, 26:493-498.
68. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New Engl J Med 2012, 366:109-119.
69. Valachis A., Nearchou A., Polyzos N.P., Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer 2013, 133:2245-2252.
70. Schneeweiss A., Chia S., Hickish T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013, 24:2278-2284.
71. Swain S.M., Ewer M.S., Cortes J., et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013, 18:257-264.
72. Lenihan D., Suter T., Brammer M., Neate C., Ross G., Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012, 23:791-800.
73. Aichberger K.J., Herndlhofer S., Schernthaner G.H., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011, 86:533-539.
74. Levato L., Cantaffa R., Kropp M.G., Magro D., Piro E., Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013, 90:531-532.
75. Quintas-Cardama A., Kantarjian H., Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012, 12:337-340.
76. Tefferi A., Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011, 86:610-611.
77. Coon E.A., Zalewski N.L., Hoffman E.M., Tefferi A., Flemming K.D. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 2013, 88:534-535.
78. Kristensen T., Randers E., Stentoft J. Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib. Leuk Res Rep 2012, 1:1-3.
79. Mirault T, Rea D, Azarine A, Messas E. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome. Eur J Haematol 2014. http://dx.doi.org/10.1111/ejh.12367.
80. Kim T.D., Rea D., Schwarz M., et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013, 27:1316-1321.
81. Mattei D., Feola M., Orzan F., Mordini N., Rapezzi D., Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009, 43:967-968.
82. Montani D., Bergot E., Gunther S., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012, 125:2128-2137.
83. Pullamsetti S.S., Berghausen E.M., Dabral S., et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2012, 32:1354-1365.
84. Shah A.M., Campbell P., Rocha G.Q., et al. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J 2014, 10.1093/eurheartj/ehu035.
85. Hoeper M.M., Barst R.J., Bourge R.C., et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013, 127:1128-1138.
86. Conti E., Romiti A., Musumeci M.B., et al. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. Int J Cardiol 2013, 167:2421-2429.
87. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
88. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.
89. Schutz F.A., Je Y., Azzi G.R., Nguyen P.L., Choueiri T.K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011, 22:1404-1412.
90. Pantaleo M.A., Mandrioli A., Saponara M., et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012, 12:231.
91. Di Lorenzo G., Autorino R., Bruni G., et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20:1535-1542.
92. Darby S.C., Ewertz M., McGale P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013, 368:987-998.
93. Hoving S., Heeneman S., Gijbels M.J., et al. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. Radiother Oncol 2011, 101:100-108.
94. Hoving S., Heeneman S., Gijbels M.J., et al. Irradiation induces different inflammatory and thrombotic responses in carotid arteries of wildtype C57BL/6J and atherosclerosis-prone ApoE(-/-) mice. Radiother Oncol 2012, 105:365-370.
95. Lancellotti P., Nkomo V.T., Badano L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013, 26:1013-1032.
96. Heidenreich P.A., Schnittger I., Strauss H.W., et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007, 25:43-49.
97. Groarke J.D., Nguyen P.L., Nohria A., Ferrari R., Cheng S., Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 2014, 35:612-623.
98. Feliz V., Saiyad S., Ramarao S.M., Khan H., Leonelli F., Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011, 34:356-359.
99. Hu Y.F., Liu C.J., Chang P.M., et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 2013, 165:355-357.
100. Farmakis D., Parissis J., Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014, 63:945-953.
101. Short N.J., Connors J.M. New oral anticoagulants and the cancer patient. Oncologist 2014, 19:82-93.